Completed PHASE4 INTERVENTIONAL NCT00034385

Valganciclovir to Prevent Cytomegalovirus Infection in Kidney and Kidney/Pancreas Transplant Recipients

Pharmacokinetics of Valganciclovir in Kidney and Kidney/Pancreas Transplant Recipients

Sponsor: National Institutes of Health Clinical Center (CC)

Updated 5 times since 2017 Last updated: Jun 30, 2017 Started: Apr 24, 2002 Primary completion: Jan 30, 2007 Completion: Oct 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00034385, this PHASE4 trial focuses on Kidney Trasplant and remains completed. Sponsored by National Institutes of Health Clinical Center (CC), it has been updated 5 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Apr 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Institutes of Health Clinical Center (CC)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States